Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma

Model scores of the 29,894 trials active now.

Model score 33% for any early termination, 15% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 22% of the time (1,598 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2018-11-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: patientsrecurrentulnglioblastomabevacizumab
  Phrases that lowered it: bloodevaluateopen labelpressurealcohol
• Phase: 2 (raises risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: no earlier finished trials (lowers risk) · Sponsor's track record
• Disease area, cancer: Yes (raises risk) · Disease area
• Drug's FAERS reports with a death: 26.1% (raises risk) · Drug's FDA history
• Has a data monitoring committee: Yes (raises risk) · Design
• Design: single group (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Blinding: none (raises risk) · Design
• Sponsor's past trials: 0 (raises risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Keywords listed: 0 (raises risk) · Design
• Number of arms: 1 (raises risk) · Design
• Responsible party: sponsor (lowers risk) · Design
• Drug's FAERS reports in the prior 12 months: 744 (raises risk) · Drug's FDA history
• Collaborators: 0 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• TPI 287 in Patients With Recurrent Glioblastoma Multiforme NCT01113463 · started 2010 · scored riskier than 99% of active trials terminated
• Tinostamustine With or Without Radiation Therapy in Treating Patients With Newly Diagnosed MGMT-Unmethylated Glioblastoma NCT03452930 · started 2018 · scored riskier than 88% of active trials completed
• Partial Brain RT, Temozolomide, Chloroquine, and TTF Therapy for the Treatment of Newly Diagnosed Glioblastoma NCT04397679 · started 2021 · scored riskier than 72% of active trials terminated
• Vaccine Therapy, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme NCT01222221 · started 2010 · scored riskier than 87% of active trials completed
• Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy NCT02047214 · started 2014 · scored riskier than 82% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.